US4101647A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Oral dosage form for X-ray contrast media containing a pharmaceutically acceptable base and method of use thereof
Assignee: Bayer Pharma AG
•
Filing: 1976-01-26
•
Granted: 1978-07-18
•
Expires: 1996-01-26
Abstract
Abstract An oral dosage form of X-ray contrast medium for cholecystocolangiography comprises a constrast agent and an amount of a pharmaceutically acceptable base, sufficient to neutralize the stomach acid of the person ingesting it.
Inventors
- 👤 Wolfram Clauss
- 👤 Ulrich Speck
- 👤 Dietmar Jentsch
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 15:06
CPC Classifications
A; A61; A61K; A61K49/00; A61K49/04; A61K49/0433; A61K49/0447; A61K49/0495; Y; Y10; Y10S; Y10S424/00; Y10S424/90
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
55 words
In a pharmaceutical composition adapted for oral administration, comprising in unit dosage form, an X-ray contrast agent for cholecystocholangiography in admixture with a pharmaceutically-acceptable carrier, the improvement wherein the composition comprises an amount per unit dosage of a pharmaceutically-acceptable base effective to neutralize the stomach acid content of a human when the composition is ingested.
Claim 2
Dependent Claim
55 words
In a pharmaceutical composition adapted for oral administration, comprising in unit dosage form, an X-ray contrast agent for cholecystocholangiography in admixture with a pharmaceutically-acceptable carrier, the improvement wherein the composition comprises an amount per unit dosage of a pharmaceutically-acceptable base effective to neutralize the stomach acid content of a human when the composition is ingested.
Claim 3
Dependent Claim
16 words
The composition of claim 1, wherein the contrast agent is a polyiodoaromatic acid or salt thereof.
Claim 4
Dependent Claim
13 words
The composition of claim 1, wherein the amount of base is 0.5-10 g.
Claim 5
Dependent Claim
10 words
The composition of claim 1, in tablet or powder form.
Claim 6
Dependent Claim
22 words
The composition of claim 1, which contains, per dosage unit, 3-10 g. of the contrast agent and 0.5-10 g. of the base.
Claim 7
Dependent Claim
13 words
The composition of claim 1, wherein the contrast agent is succinic acid mono-2,4,6-triiodo-3-methylamino-N-ethylanilide.
Claim 8
Dependent Claim
12 words
The composition of claim 1, wherein the base is NaHCO 3 .
Claim 9
Dependent Claim
12 words
The composition of claim 6, wherein the base is NaHCO 3 .
Claim 10
Independent Claim
38 words
A method for orally administering an X-ray contrast medium for cholecystocholangiography comprising administering orally to the patient concurrently with the contrast agent an amount of a physiologically-acceptable base sufficient to neutralize the stomach acid content of said patient.
Claim 11
Independent Claim
38 words
A method for orally administering an X-ray contrast medium for cholecystocholangiography comprising administering orally to the patient concurrently with the contrast agent an amount of a physiologically-acceptable base sufficient to neutralize the stomach acid content of said patient.
Claim 12
Dependent Claim
16 words
The method of claim 9, wherein the contrast agent is a polyiodoaromatic acid or salt thereof.
Claim 13
Dependent Claim
18 words
The method of claim 9, wherein the contrast agent and the base are administered in one unitary dosage.
Claim 14
Dependent Claim
18 words
The method of claim 9, wherein the contrast agent and the base are administered in separate unitary dosages.
Claim 15
Dependent Claim
13 words
The method of claim 9, wherein the contrast agent is succinic acid mono-2,4,6-triiodo-3-methylamino-N-ethylanilide.
Claim 16
Dependent Claim
12 words
The method of claim 9, wherein the base is NaHCO 3 .
Claim 17
Dependent Claim
12 words
The method of claim 13, wherein the base is NaHCO 3 .
Claim 18
Dependent Claim
14 words
The method of claim 9, wherein the dosage of the base is 0.5-10 g.
Claim 19
Dependent Claim
22 words
The method of claim 11, wherein the unitary dosage contains 3-10 g. of the contrast agent and 0.5-10 g. of the base.
References Cited (Backward Citations)
US2940996A
Cited
US2307189A
Cited
US2659690A
Cited
US2996433A
Cited
US3359278A
Cited
FR1437666A
Cited
US3553260A
Cited
US3666803A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-07-17 | 1982-01-16 | 1982-07-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-07-17 | 1986-01-16 | 1986-07-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-07-17 | 1990-01-16 | 1990-07-18 | $7700.00 | Window Closed / Lapsed |